A call to action: We need the right incentives to guide ethical innovation in neurotech and healthcare

_______________ Ana Maiques, CEO and founder of neurotech company Neuroelectrics, writes up a compelling case in her recent article, summarized thus: “I strongly believe that Neurotech entrepreneurs can not afford not to be involved in neuroethics. It is simply not an option anymore.” I share that belief and would like to take it one step further: “I strongly believe that healthcare practitioners, researchers, executives and regulators can not afford not to be involved in neuroethics. It is simply not an option anymore.” Having spent 10+ years tracking and analyzing the growing industry of digital brain/ mental health and non-invasive neurotechnologies, let me share why I believe so, and why we will need to set incentives right. Timely conversation to have Only ten years ago, neurotech largely remained the domain of research centers and high-end medical centers. Today, the industry is touching millions of practitioners, patients and consumers worldwide, thanks to an explosion of low-cost, non-invasive and eminently scalable technologies that can be used to assess and/ or to improve brain and mental health. At the recent 2019 SharpBrains Virtual Summit, which I helped produce from May 7th to the 9th, Dr. Tom Insel –former Director of the National Institute for Mental Health (NIMH) turned Google executive turned entrepreneur– surveyed the ongoing revolution in digital biomarkers and therapeutics and why it matters: While brain/ mental healthcare has failed so far be...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology Brain-health digital biomarkers digital therapeutics Mental-Health Neuroelectrics Neuroethics neurological monitoring neurotechnologies Source Type: blogs